NCT07177196View on ClinicalTrials.gov

Personalized Antisense Oligonucleotide Therapy for a Single Participant With PRPH2 Mutation Associated With Retinal Dystrophy

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

1

Participants

Timeline

Start Date

August 28, 2025

Primary Completion Date

August 31, 2027

Study Completion Date

August 31, 2027

Conditions
Retinal Dystrophy
Interventions
DRUG

nL-PRPH2-001

Personalized antisense oligonucleotide

Trial Locations (1)

92093

University of California San Diego, San Diego

All Listed Sponsors
collaborator

University of California, San Diego

OTHER

lead

n-Lorem Foundation

OTHER